Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 15, 2013

Primary Completion Date

May 19, 2016

Study Completion Date

October 27, 2017

Conditions
NeoplasmLymphoma
Interventions
DRUG

LMP400

Top1 inhibitors such as LMP400 are potent anticancer agents because stabilizing cleavage complex formation induces replication-and transcription-mediated DNA damage and delays DNA repair, leading to apoptosis. Preclinical and clinical data indicate that baseline tumor levels of Top1 correlate strongly with ability to respond to Top1 inhibitor therapy.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01794104 - Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas | Biotech Hunter | Biotech Hunter